Changes in corneal endothelial cell density after initial Ex-PRESS drainage device implantation and its relating factors over 3 years
Changes in corneal endothelial cell density after initial Ex-PRESS drainage device implantation and its relating factors over 3 years
复制标题
首次Ex-PRESS引流装置植入后3年角膜内皮细胞密度变化及相关因素
DOI:
10.1038/s41433-021-01888-1
复制
发表时间:
2022
期刊:
影响因子:
3.9
通讯作者:
Aihara Makoto
中科院分区:
文献类型:
--
作者:
Aoyama Yurika;Sakata Rei;Fujishiro Takashi;Honjo Megumi;Shirato Shiroaki;Aihara Makoto
Background/objectivesTo investigate changes in corneal endothelial cell density (CECD) after initial Ex-PRESS surgery in Japanese patients with open-angle glaucoma (OAG) followed-up for 36 months.Subjects/methodsCorneal specular microscopy was used to examine preoperative and postoperative (3, 6, 12, 24 and 36 months) CECD and CECD changes were analysed. Kaplan–Meier survival curve was used to examine CECD maintained at 95% level, and Cox proportional hazards model was used to detect the risk factors for CECD loss. Intraocular pressure (IOP) changes during the course were also examined.ResultsA total of 79 eyes of 79 patients (standalone surgery, 24 cases; combined cataract surgery, 55 cases) were investigated. Preoperative CECD (mean ± SD) was 2521 ± 305 cells/mm² and 2429 ± 366 (P= 0.003, adjusted for Bonferroni correction), 2462 ± 332 (P= 0.002), 2457 ± 317 (P< 0.001), 2433 ± 333 (P< 0.001), and 2387 ± 352 (P< 0.001) at 3, 6, 12, 24 and 36 months, respectively. The decrease rate was calculated as 1.8%/year. Further, 95% maintenance CECD at 36 months was 50.0% (95% confidence interval, 37.1–63.0%). Both univariate and multivariate Cox proportional hazard models showed that a low preoperative CECD was a significant risk factor for CECD loss. Baseline IOP of 19.3 ± 5.8 mmHg decreased at all measurement points (P< 0.001) after surgery.ConclusionCECD after initial Ex-PRESS surgery in 36 months might not be clinically problematic. However, longer-term follow-up is necessary, and regular CECD measurement should be performed, especially in patients with low CECD.